Korsana Biosciences, Inc.CYCN

Korsana Biosciences, Inc. (CYCN) is focused on neurology and psychiatry. The company is developing KRSA-028, which is currently in IND-enabling status. Interim clinical PoC data for KRSA-028 is expected by YE27, with a Phase 1 healthy volunteer data readout anticipated in mid-2027. Interim proof of concept data measuring amyloid plaque clearance in Alzheimer’s patients for KRSA-028 is expected at the end of 2027.

The company's therapeutic focus is in an area with significant unmet needs, as evidenced by the 7M+ prevalent US patients with Alzheimer's disease and an annual cost of care for Alzheimer's disease of ~$400 B in the United States. There are 2 approved disease-modifying therapies for Alzheimer's disease in the United States. Other therapies in the field have shown varying results; for example, trontinemab resulted in ~78% and 91% of patients being amyloid negative, and Gantenerumab resulted in ~28% of patients being amyloid negative. The mean remaining amyloid burden after 7 doses of trontinemab (Ph1/2, 3.6 mg/kg) was 5 CL. The amyloid negativity cutoff is 24.1 centiloids.

Safety considerations in the field include ARIA-E rates for remternetug (IV dosing), which have been observed at 50% (N=4), 60% (N=10), 0% (N=7), 8% (N=5), and 25% (N=10). The critical risk period for ARIA-E for Lecanemab is ~6 months, and the ARIA-E accumulation period for Donanemab is ~9 months. Korsana Biosciences, Inc. was formed through a merger where pre-merger Korsana stockholders own 98.5% of the combined company, and pre-merger Cyclerion shareholders own 1.5%. The expected closing of the merger transaction is in the third quarter of 2026.